基本信息
浏览量:2
职业迁徙
个人简介
The Immune Regulation and Tumour Immunotherapy group at the UCL Cancer Institute aims to investigate the interplay between the immune system and cancer throughout tumour progression and immunotherapy. The use of our own immune system to specifically target cancerous cells has become a promising approach in the fight against cancer. However, anti-tumour immunity is tightly regulated by cellular and molecular circuits that prevent self and tumour destruction and significantly limit the efficacy of existing therapies.
CD4+ T cells play a key role in the regulation of immune responses to self and foreign antigens, differentiating into various subsets of helper and regulatory T cells and instructing the function of CD8+ T cells, NK cells and macrophages. Nonetheless, little is still known about the biology of tumour-reactive CD4+ T cells during tumour progression and cancer immunotherapy.
Our aim is to identify and target the most relevant cellular and molecular pathways restricting the activation of tumour-reactive lymphocytes, their access to the tumour site, and their activity within the tumour microenvironment. Moreover, we are interested in how the function and plasticity of tumour-reactive CD4+ T cells and the innate immune compartment is regulated by the tumour microenvironment and by immune co-inhibitory (e.g. CTLA-4 and PD-1) and co-stimulatory signals (e.g. GITR, OX40, CD27). In addition, we are interested in understanding how these regulatory circuits control the efficacy of cellular vaccination and adoptive cell transfer strategies and how can they be manipulated to induce potent anti-tumour immunity.
These studies will not only inform the basic understanding of the immune response to malignancies, but in the context of the UCL Cancer Institute, will be used as a platform for the development of novel translational strategies in the clinic.
CD4+ T cells play a key role in the regulation of immune responses to self and foreign antigens, differentiating into various subsets of helper and regulatory T cells and instructing the function of CD8+ T cells, NK cells and macrophages. Nonetheless, little is still known about the biology of tumour-reactive CD4+ T cells during tumour progression and cancer immunotherapy.
Our aim is to identify and target the most relevant cellular and molecular pathways restricting the activation of tumour-reactive lymphocytes, their access to the tumour site, and their activity within the tumour microenvironment. Moreover, we are interested in how the function and plasticity of tumour-reactive CD4+ T cells and the innate immune compartment is regulated by the tumour microenvironment and by immune co-inhibitory (e.g. CTLA-4 and PD-1) and co-stimulatory signals (e.g. GITR, OX40, CD27). In addition, we are interested in understanding how these regulatory circuits control the efficacy of cellular vaccination and adoptive cell transfer strategies and how can they be manipulated to induce potent anti-tumour immunity.
These studies will not only inform the basic understanding of the immune response to malignancies, but in the context of the UCL Cancer Institute, will be used as a platform for the development of novel translational strategies in the clinic.
研究兴趣
论文共 209 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
NATURE REVIEWS CANCERno. 1 (2024): 51-71
Nature Reviews Cancerno. 1 (2024): 51-71
Hugh O'Brien,Max Salm, Laura T Morton, Maciej Szukszto, Felix O'Farrell, Charlotte Boulton,Pablo D Becker,Yardena Samuels,Charles Swanton,Marc R Mansour,Sine Reker Hadrup,Sergio A Quezada
Nature cancerno. 4 (2024): 692-692
Hugh O'Brien,Max Salm, Laura T. Morton, Maciej Szukszto, Felix O'Farrell, Charlotte Boulton,Pablo D. Becker,Yardena Samuels,Charles Swanton, Marc R. Mansour,Sine Reker Hadrup,Sergio A. Quezada
NATURE CANCER (2024)
Hugh O'Brien,Max Salm, Laura Morton, Maciej Szukszto, Felix O'Farrell, Charlotte Boulton,Pablo D Becker,Yardena Samuels,Charles Swanton,Marc R Mansour,Sine Reker Hadrup,Sergio A Quezada
Nature cancerno. 12 (2023): 1618-1621
crossref(2023)
crossref(2023)
ONCOIMMUNOLOGYno. 1 (2023)
Nature reviews. Drug discoveryno. 12 (2023): 996-1017
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn